Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Cancer statistics, 1998

Sarah Landis, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 1998 · 2.4K citations · Full text

Medicine, Biostatistics, Oncology +17

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text

Life Sciences, Immunology, Pathology +14

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

M. S. Czuczman, A.J. Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 1999 · 856 citations

Medicine, Hematology, Oncology +15